

10576267

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:44:01 ON 02 FEB 2009

=>

10576267

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:44:15 ON 02 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0

DICTIONARY FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10576267.str

10576267



chain nodes :
12 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
5-12 7-12 11-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
3-4 4-5 5-12 7-12 11-14
exact bonds :
1-2 1-5 2-3
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

G1:A,Ak,NH,CO2H


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d 11

10576267

L1 HAS NO ANSWERS
L1 STR



G1 A, Ak, NH, CO₂H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:44:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 99 TO ITERATE

100.0% PROCESSED 99 ITERATIONS 38 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1384 TO 2576
PROJECTED ANSWERS: 391 TO 1129

L2 38 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:44:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1847 TO ITERATE

100.0% PROCESSED 1847 ITERATIONS 675 ANSWERS
SEARCH TIME: 00.00.01

L3 675 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'HCAPLUS' ENTERED AT 11:44:51 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

10576267

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Feb 2009 VOL 150 ISS 6
FILE LAST UPDATED: 1 Feb 2009 (20090201/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 43 L3

=> FIL REGISTRY	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	11.40	197.50

FILE 'REGISTRY' ENTERED AT 11:47:30 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0
DICTIONARY FILE UPDATES: 30 JAN 2009 HIGHEST RN 1098270-10-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10576267a.str

10576267



chain nodes :
12 15 16 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
5-12 7-12 11-15 15-16 15-18 16-17
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
3-4 4-5 5-12 7-12 11-15 15-16 16-17
exact bonds :
1-2 1-5 2-3 15-18
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

G1:A,Ak,NH,CO2H


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 A,Ak,NH,CO2H

10576267

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 11:47:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4 TO 200

PROJECTED ANSWERS: 3 TO 163

L6 3 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 11:47:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 124 TO ITERATE

100.0% PROCESSED 124 ITERATIONS


62 ANSWERS

SEARCH TIME: 00.00.01

L7 62 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10576267b.str



chain nodes :

12 15 16 17 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

5-12 7-12 11-15 15-16 15-18 16-17 16-19

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

3-4 4-5 5-12 7-12 11-15 15-16 16-17 16-19

exact bonds :

1-2 1-5 2-3 15-18

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 :

G1:A,Ak,NH,CO2H

10576267

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

L8 STRUCTURE UPLOADED

=> d l8

L8 HAS NO ANSWERS

L8 STR



G1 A,Ak,NH,CO2H

Structure attributes must be viewed using STN Express query preparation.

=> s l8

SAMPLE SEARCH INITIATED 11:49:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s l8 sss full

FULL SEARCH INITIATED 11:50:05 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 3 ANSWERS

SEARCH TIME: 00.00.01

L10 3 SEA SSS FUL L8

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

10576267

FULL ESTIMATED COST

372.72

570.22

FILE 'HCAPLUS' ENTERED AT 11:50:10 ON 02 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Feb 2009 VOL 150 ISS 6
FILE LAST UPDATED: 1 Feb 2009 (20090201/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:44:01 ON 02 FEB 2009)

FILE 'REGISTRY' ENTERED AT 11:44:15 ON 02 FEB 2009

L1 STRUCTURE UPLOADED
L2 38 S L1
L3 675 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:51 ON 02 FEB 2009

L4 43 S L3

FILE 'REGISTRY' ENTERED AT 11:47:30 ON 02 FEB 2009

L5 STRUCTURE UPLOADED
L6 3 S L5
L7 62 S L5 SSS FULL
L8 STRUCTURE UPLOADED
L9 0 S L8
L10 3 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:50:10 ON 02 FEB 2009

=> s 17

L11 4 L7

=> s 110

L12 4 L10

=> d l11 ibib abs hitstr tot

L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:259908 HCAPLUS

DOCUMENT NUMBER: 146:309313

TITLE: Use of aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treating multiple myeloma

INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre

PATENT ASSIGNEE(S): Ab Science, Fr.

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026251	A2	20070308	WO 2006-IB3111	20060713
WO 2007026251	A3	20070712		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1904065	A2	20080402	EP 2006-820848	20060713
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080207572	A1	20080828	US 2008-995592	20080114
PRIORITY APPLN. INFO.:			US 2005-698937P	P 20050714
			WO 2006-IB3111	W 20060713

OTHER SOURCE(S): MARPAT 146:309313

AB The invention relates to a method for treating Multiple Myeloma, FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual c-kit/FGFR3 inhibitor, e.g. 2-aminoarylthiazoles and 2-aminoaryloxazoles.

IT 928298-11-7 928298-14-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treatment of multiple myeloma)

RN 928298-11-7 HCAPLUS

CN Benzamide, N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)


10576267



RN 928298-14-0 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
(11 β ,16 α)-, mixt. with N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide (CA INDEX NAME)

CM 1


CRN 928298-11-7
CMF C25 H17 F3 N4 O2



CM 2

CRN 50-02-2
CMF C22 H29 F O5

Absolute stereochemistry.



L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:395287 HCAPLUS

DOCUMENT NUMBER: 142:447205

TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3

INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethlen, Bruno

PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche Scientifique CNRS; Institut Curie

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040139	A2	20050506	WO 2004-IB3698	20041022
WO 2005040139	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283162	A1	20050506	AU 2004-283162	20041022
CA 2542909	A1	20050506	CA 2004-2542909	20041022
EP 1684750	A2	20060802	EP 2004-791783	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015467	A	20061219	BR 2004-15467	20041022
JP 2007509130	T	20070412	JP 2006-536215	20041022
CN 1950347	A	20070418	CN 2004-80037159	20041022
US 20070142390	A1	20070621	US 2006-576267	20060418
IN 2006DN02206	A	20070420	IN 2006-DN2206	20060421

10576267

MX 2006004581	A	20061120	MX 2006-4581	20060424
NO 2006002308	A	20060522	NO 2006-2308	20060522
KR 2006118500	A	20061123	KR 2006-710034	20060523
PRIORITY APPLN. INFO.:			US 2003-513214P	P 20031023
			WO 2004-IB3698	W 20041022
OTHER SOURCE(S):		CASREACT 142:447205; MARPAT 142:447205		
GI				



AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further elaborated to give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC₅₀ values of less than 1 μ M. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.


IT 851317-91-4P 851318-09-7P 851318-20-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

10576267

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit,
bcr-abl, FGFR3, and/or Flt-3)


RN 851317-91-4 HCAPLUS

CN Benzamide, 3-(dimethylamino)-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851318-09-7 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 851318-20-2 HCAPLUS

CN 1-Piperazineacetamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



IT 851317-75-4P 851317-76-5P 851317-77-6P
851317-78-7P 851317-79-8P 851317-80-1P


851317-81-2P 851317-82-3P 851317-83-4P
 851317-84-5P 851317-85-6P 851317-88-9P
 851317-90-3P 851317-92-5P 851317-93-6P
 851317-94-7P 851317-95-8P 851317-96-9P
 851317-97-0P 851317-98-1P 851317-99-2P
 851318-00-8P 851318-01-9P 851318-02-0P
 851318-03-1P 851318-04-2P 851318-05-3P
 851318-06-4P 851318-07-5P 851318-08-6P
 851318-10-0P 851318-11-1P 851318-12-2P
 851318-13-3P 851318-14-4P 851318-15-5P
 851318-16-6P 851318-17-7P 851318-18-8P
 851318-19-9P 851318-21-3P 851318-22-4P
 851318-23-5P 851318-24-6P 851318-25-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit,
 bcr-abl, FGFR3, and/or Flt-3)


RN 851317-75-4 HCAPLUS

CN Acetamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA
 INDEX NAME)



RN 851317-76-5 HCAPLUS


CN Acetamide, 2-cyano-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-77-6 HCAPLUS


10576267

CN Acetamide, 2-ethoxy-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851317-78-7 HCAPLUS

CN Propanamide, 3-methoxy-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-79-8 HCAPLUS

CN Urea, N-(4-methylphenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851317-80-1 HCAPLUS

CN Urea, N-(4-cyanophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-


10576267

oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851317-81-2 HCAPLUS

CN Urea, N-(4-fluorophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-82-3 HCAPLUS


CN Urea, N-(2-fluorophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-83-4 HCAPLUS


CN Urea, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10576267




RN 851317-84-5 HCAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851317-85-6 HCAPLUS

CN Urea, N-[4-methyl-3-[[5-phenyl-2-oxazolyl]amino]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851317-88-9 HCAPLUS


CN 5-Oxazoleacetic acid, 2-[[2-methyl-5-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-, ethyl ester (CA INDEX NAME)



10576267


RN 851317-90-3 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851317-92-5 HCAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-93-6 HCAPLUS


CN Benzamide, N-[4-methoxy-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-94-7 HCAPLUS


CN Benzamide, 4-[[3-(dimethylamino)propyl]amino]-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)

10576267




RN 851317-95-8 HCAPLUS

CN Benzamide, N-[4-fluoro-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-96-9 HCAPLUS


CN 1H-Indole-6-carboxamide, N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851317-97-0 HCAPLUS


CN Benzamide, 3-(1-methylethoxy)-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)

10576267




RN 851317-98-1 HCAPLUS

CN Benzamide, N-[4-methyl-3-[[5-(2-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851317-99-2 HCAPLUS


CN Benzamide, 3,5-dimethoxy-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-00-8 HCAPLUS


CN Benzamide, N-[3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)

10576267




RN 851318-01-9 HCAPLUS

CN Benzamide, N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-02-0 HCAPLUS


CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-03-1 HCAPLUS


CN Benzamide, N-[4-chloro-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)

10576267




RN 851318-04-2 HCAPLUS

CN 1,4-Benzenedicarboxamide, N1-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-05-3 HCAPLUS


CN 4-Isioxazolecarboxamide, 5-methyl-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-06-4 HCAPLUS


CN Benzamide, 4-cyano-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)

10576267




RN 851318-07-5 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-08-6 HCAPLUS


CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-oxazolyl]amino]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 851318-10-0 HCAPLUS


CN Carbamic acid, [2-methyl-5-[[2-methylpropoxy]carbonyl]amino]phenyl][5-(3-pyridinyl)-2-oxazolyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

10576267




RN 851318-11-1 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 851318-12-2 HCAPLUS


CN Benzeneacetamide, 4-methyl-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-13-3 HCAPLUS


CN Benzeneacetamide, 4-fluoro-N-[4-methoxy-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)

10576267




RN 851318-14-4 HCAPLUS

CN Benzeneacetamide, 2,4-difluoro-N-[4-methyl-3-[(5-phenyl-2-oxazolyl)amino]phenyl]- (CA INDEX NAME)




RN 851318-15-5 HCAPLUS

CN Benzeneacetamide, 3-bromo-N-[4-methyl-3-[[5-(2-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-16-6 HCAPLUS


CN Benzenepropanamide, 4-fluoro-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



10576267


RN 851318-17-7 HCAPLUS

CN Benzeneacetamide, 4-fluoro-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




RN 851318-18-8 HCAPLUS

CN Benzeneacetamide, N-[3-[[5-(4-cyanophenyl)-2-oxazolyl]amino]-4-methylphenyl]-2,4-difluoro- (CA INDEX NAME)



RN 851318-19-9 HCAPLUS


CN Pentanamide, 4-methyl-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-21-3 HCAPLUS


CN 1-Piperazinepropanamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)

10576267




RN 851318-22-4 HCAPLUS

CN Benzeneacetamide, 2,6-dichloro-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-23-5 HCAPLUS


CN 1-Pyrrolidinepropanamide, N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



RN 851318-24-6 HCAPLUS


CN Benzeneacetamide, N-[4-methoxy-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)

10576267



RN 851318-25-7 HCAPLUS

CN Benzeneacetamide, 4-methoxy-N-[4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)




IT 851318-39-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)

RN 851318-39-3 HCAPLUS

CN Acetamide, 2-chloro-N-[4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

7



THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

10576267

ACCESSION NUMBER: 2004:2836 HCAPLUS
DOCUMENT NUMBER: 140:77135
TITLE: Preparation of oxazolylureidoanilines as inhibitors of
serine proteases such as Factor VIIa.
INVENTOR(S): Slusasrchyk, William A.; Bolton, Scott A.; Herpin,
Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley,
E. Scott
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000788	A1	20031231	WO 2003-US19605	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003245614	A1	20040106	AU 2003-245614	20030617
US 20040019085	A1	20040129	US 2003-464035	20030617
US 6846838	B2	20050125		
EP 1551794	A1	20050713	EP 2003-739243	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-389832P	P 20020619
			WO 2003-US19605	W 20030617
OTHER SOURCE(S):		MARPAT 140:77135		
GI				



AB Title compds. [1; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R4, R5 = H, halo, OH, cyano, alkoxy, OCF3, amino, etc.; R6 = H, (substituted) alkyl; R7, R8 = H, halo, OH, cyano, alkoxy, CF3, OCF3, amino, (substituted) alkyl, etc.; R9, R10 = H, (substituted) alkyl; NR9R10 = 3-8 membered (substituted) heterocyclyl; R11 = 0-4 halo, cyano, NO2, (substituted) alkyl, alkenyl, alkynyl, etc.; R12 = H, (substituted) alkyl; R13, R14 = H, (substituted) alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.


IT 639475-69-7P 639475-73-3P 639475-75-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa)

RN 639475-69-7 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-[(aminocarbonyl)amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639475-73-3 HCAPLUS


CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-[[(methylamino) carbonyl] amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 639475-72-2


CMF C24 H25 N7 O4

10576267




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 639475-75-5 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-[[[(ethylamino)carbonyl]amino]-4-(2-oxazolyloxy)phenyl]amino]-5-oxazolyloxy]phenyl]methyl]-N-methyl- (CA INDEX NAME)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:755249 HCAPLUS
DOCUMENT NUMBER: 137:263025
TITLE: Preparation of substituted oxazoles as IMPDH inhibitors
INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts,

William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi,
 Gregory S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S.
 Ser. No. 428,432.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129
US 6596747	B2	20030722		
US 6399773	B1	20020604	US 1999-428432	19991027
WO 2003047512	A2	20030612	WO 2002-US38038	20021127
WO 2003047512	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352950	A1	20030617	AU 2002-352950	20021127
EP 1448187	A2	20040825	EP 2002-789910	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:				
			US 1998-106186P	P 19981029
			US 1999-428432	A2 19991027
			US 2001-997963	A 20011129
			WO 2002-US38038	W 20021127
OTHER SOURCE(S): MARPAT 137:263025				
GI				



- AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R³, R⁴; R³ = 5-6-membered (un)saturated heterocyclic ring; R⁴ = H, halo, NO, CF₃, alkyl, alkoxy, etc.; R = H, alkyl; R¹-2 = H, halo, NO₂, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimide (CH₃CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.
- IT 463941-52-8P, N-[2-[2-((3-Acetylaminophenyl)amino)oxazol-5-yl]benzyl]-2-amino-N-methylacetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)
- RN 463941-52-8 HCAPLUS
- CN Acetamide, N-[[2-[2-[[3-(acetylamino)phenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (CA INDEX NAME)



=> d l11 ibib abs tot

L11 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN



ACCESSION NUMBER: 2007:259908 HCAPLUS
 DOCUMENT NUMBER: 146:309313
 TITLE: Use of aminoarylthiazole and aminoaryloxazole dual
 c-kit/FGFR3 inhibitors for treating multiple myeloma
 INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre
 PATENT ASSIGNEE(S): Ab Science, Fr.
 SOURCE: PCT Int. Appl., 31pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026251	A2	20070308	WO 2006-IB3111	20060713
WO 2007026251	A3	20070712		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1904065	A2	20080402	EP 2006-820848	20060713
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080207572	A1	20080828	US 2008-995592	20080114
PRIORITY APPLN. INFO.:			US 2005-698937P	P 20050714
			WO 2006-IB3111	W 20060713

OTHER SOURCE(S): MARPAT 146:309313
 AB The invention relates to a method for treating Multiple Myeloma, FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual c-kit/FGFR3 inhibitor, e.g. 2-aminoarylthiazoles and 2-aminoaryloxazoles.

L11 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:395287 HCAPLUS
 DOCUMENT NUMBER: 142:447205
 TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3
 INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethlen, Bruno
 PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche Scientifique CNRS; Institut Curie
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040139	A2	20050506	WO 2004-IB3698	20041022
WO 2005040139	A3	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283162	A1	20050506	AU 2004-283162	20041022
CA 2542909	A1	20050506	CA 2004-2542909	20041022
EP 1684750	A2	20060802	EP 2004-791783	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004015467	A	20061219	BR 2004-15467	20041022
JP 2007509130	T	20070412	JP 2006-536215	20041022
CN 1950347	A	20070418	CN 2004-80037159	20041022
US 20070142390	A1	20070621	US 2006-576267	20060418
IN 2006DN02206	A	20070420	IN 2006-DN2206	20060421
MX 2006004581	A	20061120	MX 2006-4581	20060424
NO 2006002308	A	20060522	NO 2006-2308	20060522
KR 2006118500	A	20061123	KR 2006-710034	20060523
PRIORITY APPLN. INFO.:			US 2003-513214P	P 20031023
			WO 2004-IB3698	W 20041022
OTHER SOURCE(S):	CASREACT 142:447205; MARPAT 142:447205			
GI				



AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further elaborated to give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC₅₀ values of less than 1 μ M. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:2836 HCAPLUS

DOCUMENT NUMBER: 140:77135

TITLE: Preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa.

INVENTOR(S): Slusasrchyk, William A.; Bolton, Scott A.; Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott



PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000788	A1	20031231	WO 2003-US19605	20030617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003245614	A1	20040106	AU 2003-245614	20030617
US 20040019085	A1	20040129	US 2003-464035	20030617
US 6846838	B2	20050125		
EP 1551794	A1	20050713	EP 2003-739243	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-389832P	P 20020619
			WO 2003-US19605	W 20030617

OTHER SOURCE(S): MARPAT 140:77135
 GI



AB Title compds. [I; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R₄, R₅ = H, halo, OH, cyano, alkoxy, OCF₃, amino, etc.; R₆ = H, (substituted) alkyl; R₇, R₈ = H, halo, OH, cyano, alkoxy, CF₃, OCF₃, amino, (substituted) alkyl, etc.; R₉, R₁₀ = H, (substituted) alkyl; NR₉R₁₀ = 3-8 membered (substituted) heterocyclyl; R₁₁ = 0-4 halo, cyano, NO₂, (substituted) alkyl, alkenyl, alkynyl, etc.; R₁₂ = H, (substituted) alkyl; R₁₃, R₁₄ = H, (substituted)

alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:755249 HCAPLUS

DOCUMENT NUMBER: 137:263025

TITLE: Preparation of substituted oxazoles as IMPDH inhibitors

INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129
US 6596747	B2	20030722		
US 6399773	B1	20020604	US 1999-428432	19991027
WO 2003047512	A2	20030612	WO 2002-US38038	20021127
WO 2003047512	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352950	A1	20030617	AU 2002-352950	20021127
EP 1448187	A2	20040825	EP 2002-789910	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:				
			US 1998-106186P	P 19981029
			US 1999-428432	A2 19991027
			US 2001-997963	A 20011129
			WO 2002-US38038	W 20021127
OTHER SOURCE(S): MARPAT 137:263025				
GI				



AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimide (CH3CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.

=> d his

(FILE 'HOME' ENTERED AT 11:44:01 ON 02 FEB 2009)

FILE 'REGISTRY' ENTERED AT 11:44:15 ON 02 FEB 2009

L1 STRUCTURE UPLOADED
L2 38 S L1
L3 675 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:44:51 ON 02 FEB 2009

L4 43 S L3

FILE 'REGISTRY' ENTERED AT 11:47:30 ON 02 FEB 2009

L5 STRUCTURE UPLOADED
L6 3 S L5
L7 62 S L5 SSS FULL
L8 STRUCTURE UPLOADED
L9 0 S L8
L10 3 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:50:10 ON 02 FEB 2009

L11 4 S L7
L12 4 S L10

10576267

=> s 14 and py<=2003
24034228 PY<=2003
L13 20 L4 AND PY<=2003

=> s 113 and p/dt
6538018 P/DT
L14 11 L13 AND P/DT

=> s 114 and us/pc
1892403 US/PC
L15 8 L14 AND US/PC

=> d 115 ibib abs hitstr tot

L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:2836 HCAPLUS

DOCUMENT NUMBER: 140:77135

TITLE: Preparation of oxazolylureidoanilines as inhibitors of
serine proteases such as Factor VIIa.

INVENTOR(S): Slusarschyk, William A.; Bolton, Scott A.; Herpin,
Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley,
E. Scott

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000788	A1	20031231	WO 2003-US19605	20030617 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003245614	A1	20040106	AU 2003-245614	20030617
US 20040019085	A1	20040129	US 2003-464035	20030617 <--
US 6846838	B2	20050125		
EP 1551794	A1	20050713	EP 2003-739243	20030617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-389832P	P 20020619
			WO 2003-US19605	W 20030617
OTHER SOURCE(S):	MARPAT 140:77135			
GI				



AB Title compds. [I; A = 0-1 5-6 membered (unsatd.) (substituted) carbocyclyl, heterocyclyl, heteroaryl; B = (substituted) oxazolyl, triazolyl, pyrazolyl, imidazolyl; D = (substituted) phenylene, 5-6 membered heteroaryl, heterocyclyl, cycloalkyl; R4, R5 = H, halo, OH, cyano, alkoxy, OCF3, amino, etc.; R6 = H, (substituted) alkyl; R7, R8 = H, halo, OH, cyano, alkoxy, CF3, OCF3, amino, (substituted) alkyl, etc.; R9, R10 = H, (substituted) alkyl; NR9R10 = 3-8 membered (substituted) heterocyclyl; R11 = 0-4 halo, cyano, NO2, (substituted) alkyl, alkenyl, alkynyl, etc.; R12 = H, (substituted) alkyl; R13, R14 = H, (substituted) alkyl, cyano, OH, alkoxy, cycloalkyl, heterocyclyl, etc.], were prepared as Factor VIIa inhibitors (no data). Thus, title compound (II) was prepared in 11 steps.


IT 639475-69-7P 639475-73-3P 639475-75-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolylureidoanilines as inhibitors of serine proteases such as Factor VIIa)

RN 639475-69-7 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-[(aminocarbonyl)amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639475-73-3 HCAPLUS


CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-[[(methylamino)carbonyl]amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

10576267

CM 1

CRN 639475-72-2


CMF C24 H25 N7 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 639475-75-5 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-[[[(ethylamino)carbonyl]amino]-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



IT 639475-88-0P 639475-91-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of oxazolylureidoanilines as inhibitors of serine proteases)

10576267

such as Factor VIIa)


RN 639475-88-0 HCAPLUS

CN Benzoic acid, 5-[[5-[2-[[[2-[(1,1-dimethylethoxy)carbonyl]amino]acetyl]methylamino]methyl]phenyl]-2-oxazolyl]amino]-2-(2-oxazolyl)-, methyl ester (CA INDEX NAME)



RN 639475-91-5 HCAPLUS

CN Benzoic acid, 5-[[5-[2-[[[2-[(1,1-dimethylethoxy)carbonyl]amino]acetyl]methylamino]methyl]phenyl]-2-oxazolyl]amino]-2-(2-oxazolyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:2622 HCAPLUS

DOCUMENT NUMBER: 140:53429

TITLE: Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor VIIa-associated conditions

INVENTOR(S): Herpin, Timothy; Bisacchi, Gregory S.; Pi, Zulan; Priestley, E. Scott; Dhar, T. G. Murali

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 2004000214      A2      20031231      WO 2003-US19155      20030617 <--
WO 2004000214      A3      20040325
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
    PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
    TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
    KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
    FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
    BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003279182      A1      20040106      AU 2003-279182      20030617
US 20040029940      A1      20040212      US 2003-464366      20030617 <--
US 7041692          B2      20060509
EP 1532103          A2      20050525      EP 2003-742043      20030617
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 20060173057      A1      20060803      US 2006-377104      20060316 <--
PRIORITY APPLN. INFO.:      US 2002-389833P      P 20020619
                                US 2003-464366      A3 20030617
                                WO 2003-US19155      W 20030617

```

OTHER SOURCE(S): MARPAT 140:53429

AB Use of at least one compound having an amine nucleus, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in the manufacture of a medicament useful for treating conditions associated with the activity of Factor VIIa is described.


IT 1027167-49-2

RL: PRPH (Prophetic)

(Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor VIIa-associated conditions)

RN 1027167-49-2 HCAPLUS

CN Acetamide, N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl-2-(methylamino)- (CA INDEX NAME)



IT 639458-85-8P 639458-89-2P 639458-94-9P

639458-95-0P 639459-05-5P 639459-06-6P

639459-07-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of compds. for treating factor VIIa-associated conditions)

10576267


RN 639458-85-8 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 639458-89-2 HCAPLUS

CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[[3-(phenylmethoxy)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 639458-94-9 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[(2-methoxy[1,1'-biphenyl]-4-yl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639458-95-0 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[3-chloro-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)

10576267




RN 639459-05-5 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[[2-[[3-chloro-4-(2-thiazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 639459-06-6 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[[2-[[3-ethyl-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-07-7 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[[2-[[3-methoxy-4-(2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




IT 639459-18-0 639459-19-1 639459-20-4
 639459-21-5 639459-22-6 639459-23-7
 639459-24-8 639459-25-9 639459-26-0
 639459-27-1 639459-28-2 639459-29-3
 639459-30-6 639459-31-7 639459-32-8
 639459-33-9 639459-34-0 639459-35-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (use of compds. for treating factor VIIa-associated conditions)

RN 639459-18-0 HCAPLUS


CN Acetamide, 2-amino-N-[[5-fluoro-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-19-1 HCAPLUS


CN Acetamide, 2-amino-N-[1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]ethyl]-N-methyl- (CA INDEX NAME)

10576267




RN 639459-20-4 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[4-(4-ethyl-4,5-dihydro-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-21-5 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[4-(4,5-dihydro-4-methyl-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-22-6 HCAPLUS


CN Acetamide, 2-amino-N-[[5-chloro-2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)

10576267




RN 639459-23-7 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[[2-[[4-(4-ethyl-2-oxazolyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-24-8 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[[2-[[3-methoxy-4-(4-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 639459-25-9 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[[2-[[4-(3-furanyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)


10576267



RN 639459-26-0 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-methyl-5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 639459-27-1 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-methyl-2-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 639459-28-2 HCAPLUS
CN Acetamide, 2-amino-N-[[2-[2-[[4-cyano-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)

10576267




RN 639459-29-3 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(4-bromo-3-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-30-6 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(2-methyl-1-propen-1-yl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 639459-31-7 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[[4-[(hydroxyamino)iminomethyl]-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)

10576267




RN 639459-32-8 HCAPLUS

CN Acetamide, 2-amino-N-ethyl-N-[[2-[[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 639459-33-9 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)



RN 639459-34-0 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[[2-[[4-(2-furanyl)-3-methoxyphenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)

10576267



RN 639459-35-1 HCAPLUS

CN Cyclopentanecarboxamide, 1-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:755249 HCAPLUS

DOCUMENT NUMBER: 137:263025

TITLE: Preparation of substituted oxazoles as IMPDH inhibitors

INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129 <--

US 6596747 B2 20030722
 US 6399773 B1 20020604 US 1999-428432 19991027 <--
 WO 2003047512 A2 20030612 WO 2002-US38038 20021127 <--
 WO 2003047512 A3 20031016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



AU 2002352950 A1 20030617 AU 2002-352950 20021127 <--
 EP 1448187 A2 20040825 EP 2002-789910 20021127

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.:

US 1998-106186P P 19981029
 US 1999-428432 A2 19991027
 US 2001-997963 A 20011129
 WO 2002-US38038 W 20021127

OTHER SOURCE(S): MARPAT 137:263025
 GI



AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared
 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph
 cyanocarbonimide (CH3CN, reflux, 40 h) to give an intermediate which was
 reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors
 of IMPDH enzyme and/or serine protease factor VIIa.


IT 267645-41-0P, 2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-(2-

pyridinyl)oxazole 267645-42-1P,
 2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-(tetrahydro-2-furanyl)oxazole
 267645-48-7P, 5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-[[3-methoxy-4-
 (5-oxazolyl)phenyl]amino]oxazole 267645-67-0P,
 5-(2-Furanyl)-2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxazole
 267645-68-1P, 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-
 oxazolyl]-1-pyrrolidinecarboxylic acid phenylmethyl ester
 267645-93-2P, 2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-(2-
 pyrrolidinyl)oxazole 267645-94-3P,
 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-
 pyrrolidinecarboxylic acid Methyl Ester 267645-95-4P,
 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-
 methoxymethylcarbonylpyrrolidine 267645-96-5P,
 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-
 ((morpholino)methyl)carbonylpyrrolidine 267645-98-7P,
 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-
 pyrrolidinecarboxylic acid 2-(methylsulfonyl)ethyl ester
 267645-99-8P 267647-75-6P,
 2-[(3-Methoxy-4-cyanophenyl)amino]-5-phenyloxazole 463941-28-8P,
 2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-
 pyrrolidinecarboxylic acid ethyl ester 463941-31-3P,
 2-Amino-N-[2-[2-(3-methoxy-4-methylphenylamino)oxazol-5-yl]benzyl]-N-
 methylacetamide 463941-36-8P,
 2-Amino-N-[2-[2-(3-methoxyphenylamino)oxazol-5-yl]benzyl]-N-
 methylacetamide 463941-38-0P,
 2-Amino-N-[2-[2-(3-chlorophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide
 463941-42-6P, 2-Amino-N-[2-[2-(3,4-dichlorophenylamino)oxazol-5-
 yl]benzyl]-N-methylacetamide 463941-43-7P,
 2-Amino-N-[2-[2-(3-cyanophenylamino)oxazol-5-yl]benzyl]-N-methylacetamide
 463941-49-3P, 2-Amino-N-methyl-N-[2-[2-(3-nitrophenylamino)oxazol-
 5-yl]benzyl]acetamide 463941-52-8P,
 N-[2-[2-((3-Acetylaminophenyl)amino)oxazol-5-yl]benzyl]-2-amino-N-
 methylacetamide 463941-53-9P,
 3-[[5-[2-[[2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-N-
 methylbenzamide 463941-55-1P,
 4-[[5-[2-[[2-Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-2-
 methoxybenzoic acid methyl ester 463941-57-3P
 463941-64-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)

RN 267645-41-0 HCAPLUS


CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-pyridinyl)- (CA
 INDEX NAME)



RN 267645-42-1 HCAPLUS


10576267

CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(tetrahydro-2-furanyl)-
(CA INDEX NAME)




RN 267645-48-7 HCAPLUS

CN 2-Oxazolamine, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (CA INDEX NAME)




RN 267645-67-0 HCAPLUS

CN 2-Oxazolamine, 5-(2-furanyl)-N-[3-methoxy-4-(5-oxazolyl)phenyl]- (CA INDEX NAME)



RN 267645-68-1 HCAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, phenylmethyl ester (CA INDEX NAME)



RN 267645-93-2 HCAPLUS


CN 2-Oxazolamine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-5-(2-pyrrolidinyl)- (CA INDEX NAME)

10576267




RN 267645-94-3 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, methyl ester (CA INDEX NAME)




RN 267645-95-4 HCAPLUS

CN Ethanone, 2-methoxy-1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-pyrrolidinyl]- (CA INDEX NAME)



RN 267645-96-5 HCAPLUS


CN Ethanone, 1-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-1-pyrrolidinyl]-2-(4-morpholinyl)- (CA INDEX NAME)



10576267


RN 267645-98-7 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, 2-(methysulfonyl)ethyl ester (CA INDEX NAME)




RN 267645-99-8 HCAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, tetrahydro-3-furanyl ester (CA INDEX NAME)



RN 267647-75-6 HCAPLUS


CN Benzonitrile, 2-methoxy-4-[(5-phenyl-2-oxazolyl)amino]- (CA INDEX NAME)



RN 463941-28-8 HCAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-, ethyl ester (CA INDEX NAME)

10576267




RN 463941-31-3 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(3-methoxy-4-methylphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 463941-36-8 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(3-methoxyphenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-38-0 HCAPLUS


CN Acetamide, 2-amino-N-[[2-[2-[(3-chlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



10576267


RN 463941-42-6 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(3,4-dichlorophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 463941-43-7 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[(3-cyanophenyl)amino]-5-oxazolyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 463941-49-3 HCAPLUS


CN Acetamide, 2-amino-N-methyl-N-[[2-[2-[(3-nitrophenyl)amino]-5-oxazolyl]phenyl]methyl]- (CA INDEX NAME)




RN 463941-52-8 HCAPLUS

CN Acetamide, N-[[2-[2-[[3-(acetylamino)phenyl]amino]-5-oxazolyl]phenyl]methyl]-2-amino-N-methyl- (CA INDEX NAME)


10576267



RN 463941-53-9 HCAPLUS
CN Benzamide, 3-[[5-[2-[[3-amino-2-oxopropyl]amino]methyl]phenyl]-2-oxazolyl]amino]-N-methyl- (CA INDEX NAME)



RN 463941-55-1 HCAPLUS
CN Benzoic acid, 4-[[5-[2-[[3-amino-2-oxopropyl]amino]methyl]phenyl]-2-oxazolyl]amino]-2-methoxy-, methyl ester (CA INDEX NAME)




RN 463941-57-3 HCAPLUS
CN Acetamide, 2-amino-N-[[3-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-4-pyridinyl]methyl]-N-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 463941-56-2
CMF C22 H22 N6 O4


10576267



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 463941-64-2 HCAPLUS

CN Acetamide, 2-amino-N-[[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-3-pyridinyl]methyl]-N-methyl- (CA INDEX NAME)



IT 463941-62-0P 463941-63-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted oxazoles as IMPDH inhibitors)

RN 463941-62-0 HCAPLUS


CN Carbamic acid, [[3-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-4-pyridinyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10576267



RN 463941-63-1 HCAPLUS

CN 4-Pyridinemethanamine, 3-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]-N-methyl- (CA INDEX NAME)



L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:479495 HCAPLUS

DOCUMENT NUMBER: 129:108995

ORIGINAL REFERENCE NO.: 129:22397a,22400a

TITLE: Preparation of aromatic and heterocyclic amine derivatives as NOS inhibitors

INVENTOR(S): Esaki, Toru; Makino, Toshihiko; Nishimura, Yoshikazu; Nagafuji, Toshiaki

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828257	A1	19980702	WO 1997-JP4762	19971224 <--
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,			

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

CA 2275933	A1	19980702	CA 1997-2275933	19971224 <--
AU 9853394	A	19980717	AU 1998-53394	19971224 <--
AU 742388	B2	20020103		
JP 10237028	A	19980908	JP 1997-366474	19971224 <--
EP 949242	A1	19991013	EP 1997-950368	19971224 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
HU 2000000321	A2	20000828	HU 2000-321	19971224 <--
HU 2000000321	A3	20000928		
RU 2193554	C2	20021127	RU 1999-116598	19971224 <--
TW 584622	B	20040421	TW 1997-86119687	19971224
NO 9903109	A	19990824	NO 1999-3109	19990622 <--
US 6331553	B1	20011218	US 1999-331733	19990624 <--
PRIORITY APPLN. INFO.:			JP 1996-359791	A 19961224
OTHER SOURCE(S):			WO 1997-JP4762	W 19971224
GI			MARPAT 129:108995	



AB The title compds. I [R1 and R2 represent each hydrogen, etc.; R3 and R4 represent each hydrogen, lower alkyl, etc.; R5 represents hydrogen, etc.; X1, X2, X3 and X4 represent each hydrogen, lower alkoxyl, etc.; A represents an optionally substituted pyridine ring, etc.; and m and n are each 0 or 1] are prepared I are useful as pharmaceuticals for cerebrovascular disorders, etc. The title compound II in vitro showed IC50 values of 22.6 nM and 916.7 nM against nNOS and iNOS, resp.

IT 209898-14-6P 209898-16-8P 209898-18-0P
209898-20-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic and heterocyclic amine derivs. as NOS inhibitors)

10576267

RN 209898-14-6 HCAPLUS
CN 2-Oxazoline, N-[3-(aminomethyl)phenyl]-5-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 209898-13-5
CMF C11 H13 N3 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 209898-16-8 HCAPLUS
CN 2-Oxazoline, N-[3-(aminomethyl)-2-ethoxyphenyl]-5-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 209898-15-7
CMF C13 H17 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2


10576267



RN 209898-18-0 HCAPLUS
CN 2-Oxazoline, N-[3-(aminomethyl)-2-methylphenyl]-5-methyl-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 209898-17-9
CMF C12 H15 N3 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 209898-20-4 HCAPLUS
CN 2-Oxazoline, N-[3-(aminomethyl)-4-methoxyphenyl]-5-methyl-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 209898-19-1
CMF C12 H15 N3 O2


10576267



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 209899-15-0P 209899-17-2P 209899-18-3P
209899-19-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of aromatic and heterocyclic amine derivs. as NOS inhibitors)

RN 209899-15-0 HCAPLUS


CN Imidodicarbonic acid, N-[[3-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-,
C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 209899-17-2 HCAPLUS

CN Imidodicarbonic acid, N-[[2-ethoxy-3-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA
INDEX NAME)


10576267



RN 209899-18-3 HCAPLUS
CN Imidodicarbonic acid, N-[[2-methyl-3-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 209899-19-4 HCAPLUS
CN Imidodicarbonic acid, N-[[2-methoxy-5-[(5-methyl-2-oxazolyl)amino]phenyl]methyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:640645 HCAPLUS
DOCUMENT NUMBER: 127:278199
ORIGINAL REFERENCE NO.: 127:54337a,54340a
TITLE: Preparation of 2,4-diaminopyridine derivatives as

antagonists of neuropeptide Y receptors
 INVENTOR(S): Fukami, Takehiro; Mase, Toshiaki; Tsuchiya, Yoshimi;
 Kanatani, Akio; Fukuroda, Takahiro
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan; Fukami,
 Takehiro; Mase, Toshiaki; Tsuchiya, Yoshimi; Kanatani,
 Akio; Fukuroda, Takahiro
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734873	A1	19970925	WO 1997-JP890	19970319 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2249222	A1	19970925	CA 1997-2249222	19970319 <--
CA 2249222	C	20051108		
AU 9720428	A	19971010	AU 1997-20428	19970319 <--
EP 889034	A1	19990107	EP 1997-908495	19970319 <--
EP 889034	B1	20030917		
R: DE, FR, GB, IT				
JP 4106711	B2	20080625	JP 1997-533359	19970319
US 6011039	A	20000104	US 1998-142162	19981013 <--
PRIORITY APPLN. INFO.:			JP 1996-91968	A 19960321
			WO 1997-JP890	W 19970319

GI



AB Compds. of general formula [I; Ar1 = aryl or heteroaryl which may be substituted with a radical selected from the group consisting of lower alkyl, lower hydroxyalkyl, lower alkylene and NRaRb; wherein Ra, Rb = hydrogen or lower alkyl; R2, R3 = lower alkyl or alternatively R2 and R3 are united to form alkylene which may be interrupted by oxygen or sulfur and may be substituted with one or two lower alkyl radicals; R4 = hydrogen or lower alkyl which may be substituted with a radical selected from the

group consisting of hydroxyl, amino, carbamoyl, and lower alkoxycarbonyl; Ar2 = aryl or heteroaryl which may be substituted with a radical selected from the group consisting of halogeno, hydroxyl, lower alkyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower hydroxyalkyl, lower alkoxy lower alkyl, NRcRd, and NReCONRfRg; wherein Rc = hydrogen or lower alkyl; Rd = hydrogen, lower alkyl, CORh, SO2Ri, optionally substituted heterocyclyl; Re, Rf = hydrogen, lower alkyl or alkenyl, optionally substituted aryl or heteroaryl; Rh = lower alkyl or alkoxy, lower alkoxy-lower alkoxy, lower alkenyloxy or alkynyloxy, heterocyclyl-C1-3 n-alkoxy; Ri = lower alkyl or alkenyl; W = oxygen, sulfur, CHRj, or NRk; Rj, Rk = H, lower alkyl] or pharmaceutically acceptable salts thereof are prepared Agents for the treatment of hyperphagia, obesity or diabetes comprising I the active ingredients are claimed. Thus, 2-[N-tert-butoxycarbonyl-N-(3-carboxybenzyl)amino]-6-(5-ethyl-1,3,4-thiadiazol-2-ylthiomethyl)-4-morpholinopyridine (preparation given) was refluxed with (PhO)2P(O)N3, allyl alc., and Et3N in DMF for 3 h, followed by treatment with CF3CO2H to give the title compound (II). II in vitro showed IC50 of 0.33 nM for inhibiting the binding of [125I]peptide YY to membrane preparation from human neuroblastoma SKN-MC cells.


IT 196498-35-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaminopyridine derivs. as antagonists of neuropeptide Y receptors for treatment of hyperphagia, obesity, or diabetes)

RN 196498-35-8 HCAPLUS

CN 2-Pyridinamine, 6-[[[(5-ethyl-1,3,4-thiadiazol-2-yl)thio]methyl]-N-[[3-[(4-methyl-2-oxazolyl)amino]phenyl]methyl]-4-(4-morpholinyl)- (CA INDEX NAME)





IT 196500-06-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of diaminopyridine derivs. as antagonists of neuropeptide Y receptors for treatment of hyperphagia, obesity, or diabetes)

RN 196500-06-8 HCAPLUS

CN Carbamic acid, (4-methyl-2-oxazolyl)[3-[[[(methylsulfonyl)oxy]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:471590 HCAPLUS

DOCUMENT NUMBER: 115:71590

ORIGINAL REFERENCE NO.: 115:12379a,12382a

TITLE: Preparation of 2-amino-4,5-disubstituted oxazoles and -thiazoles as herbicide antidotes

INVENTOR(S): Grabiak, Raymond C.; Howe, Robert K.; Lee, Len F.

PATENT ASSIGNEE(S): Monsanto Co., USA

SOURCE: U.S., 48 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5000775	A	19910319	US 1985-815102	19851231 <--
PRIORITY APPLN. INFO.:			US 1985-815102	19851231
OTHER SOURCE(S):	MARPAT	115:71590		

GI



AB The title compds. [I; R1, R2 = H, (halo)alkyl, hydroxyalkyl, cycloalkyl, alkenyl, aryl(alkyl), etc.; R3, R4 = (hydroxy)alkyl, alkoxy(alkyl), haloalkyl, aryl(alkyl), COX, CO2R5, COSR6, CONR7R8, (un)substituted 2-oxazolyl; R5, R6 = H, (alkoxy)alkyl, agriculturally acceptable cation, aryl(alkyl); R7, R8 = H, (hydroxy)alkyl, aryl, etc.; X = halo; Z = O, S], especially effective to safen acetamide herbicides used to control grassy weeds


in sorghum and broadleaf weeds in corn, were prepared, e.g., by amination of chlorothiazoles with primary amines. Thus, a stirred mixture of Et 2-chloro-4-trifluoromethyl-5-thiazolecarboxylate and tert-butylamine was refluxed 20 h to give title compound I (R1 = H, R2 = Me3C, R3 = F3C, R4 = EtO2C, Z = S) which at 8.96 kg/ha gave 69% safening effect on sorghum when co-dispersed in soil with 2.24 kg/ha alachlor. A total of 60 I were prepared and their extensive evaluation carried out with approx. 20 herbicides. Numerous formulations containing I are given.

IT 135026-19-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide antidote)

RN 135026-19-6 HCAPLUS

CN 5-Oxazolecarboxylic acid, 4-(trifluoromethyl)-2-[[3-(trifluoromethyl)phenyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:185568 HCAPLUS

DOCUMENT NUMBER: 114:185568

ORIGINAL REFERENCE NO.: 114:31354h,31355a

TITLE: Preparation of anti-inflammatory 4-(heterocyclylamino)phenol derivatives

INVENTOR(S): Bantick, John Raymond; Hardern, David Norman; Appleton, Richard Anthony; Dixon, John; Wilkinson, David John

PATENT ASSIGNEE(S): Fisons PLC, UK

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9014338	A1	19901129	WO 1990-GB762	19900517 <--
W: AU, FI, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9056682	A	19901218	AU 1990-56682	19900517 <--
AU 630196	B2	19921022		
ZA 9003802	A	19910130	ZA 1990-3802	19900517 <--
EP 425650	A1	19910508	EP 1990-908298	19900517 <--

EP 425650	B1	19950809		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 06502384	T	19940317	JP 1990-507734	19900517 <--
JP 07116155	B	19951213		
ES 2077066	T3	19951116	ES 1990-908298	19900517 <--
RU 2049779	C1	19951210	RU 1990-4894663	19900517 <--
CA 2017169	A1	19901120	CA 1990-2017169	19900518 <--
HU 54119	A2	19910128	HU 1990-3094	19900518 <--
HU 206323	B	19921028		
DD 300544	A5	19920617	DD 1990-340830	19900518 <--
PL 164432	B1	19940729	PL 1990-285248	19900518 <--
PL 164480	B1	19940831	PL 1990-289487	19900518 <--
IL 94433	A	19950315	IL 1990-94433	19900518 <--
CZ 280637	B6	19960313	CZ 1990-2444	19900518 <--
CN 1047497	A	19901205	CN 1990-103739	19900519 <--
RO 105958	B1	19930130	RO 1990-145922	19900912 <--
NO 9100198	A	19910312	NO 1991-198	19910117 <--
US 5428044	A	19950627	US 1993-138375	19931015 <--
PRIORITY APPLN. INFO.:			GB 1989-11654	A 19890520
			GB 1989-11655	A 19890520
			GB 1990-3044	A 19900210
			WO 1990-GB762	A 19900517
			US 1991-634182	B1 19910301
			US 1992-978041	B1 19921118
OTHER SOURCE(S):			MARPAT 114:185568	
GI				



AB The title compds. [I; R1 = C(O)YZ, SO₂R₁₀; Y = single bond, O, NH, alkylimino, CO; Z = H, alkyl, alkyl substituted by ≤1 substituents selected from OH, alkoxy, acyloxy, CO₂H, alkoxycarbonyl, (un)substituted CONH₂ or NH₂, heterocyclyl, (un)substituted aryl, etc.; R₁₀ = alkyl; R₂, R₃, R₅, R₆ = H, alkyl, alkoxy, halo; R₄ = H, alkyl; X = (un)substituted heterocyclyl] are prepared as antiinflammatories (no data). Thus, acetylation of 2,6-dimethyl-4-nitrophenol with AcCl in CH₂Cl₂ containing Et₃N followed by hydrogenation over PtO₂ in EtOH gave 4-amino-2,6-dimethylphenyl acetate which was refluxed with 3-amino-4,5-dihydro-1-phenyl-1H-pyrazole in PhMe containing 4-MeC₆H₄SO₃H for 8 h to give 4-(4,5-dihydro-1-phenyl-1H-pyrazol-3-yl)amino-2,6-dimethylphenyl acetate. A total of 117 I containing heterocycles, i.e., pyrazole, benzimidazole, quinoline, pyrimidine, pyrazine, oxazole, 1,2,3-triazole, pyridazine, imidazole, 1,2,4-thiadiazole, thiophene, isoxazole, 1,2,4-triazine, and 1,3,4-thiadiazole, were prepared

IT 133356-02-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10576267

(preparation of, as antiinflammatory)

RN 133356-02-2 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-(2-oxazolylamino)-, 1-acetate (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:493070 HCAPLUS

DOCUMENT NUMBER: 109:93070

ORIGINAL REFERENCE NO.: 109:15541a,15544a

TITLE: Preparation, testing, and formulation of 4-(heterocyclyamino)phenols as inflammation inhibitors

INVENTOR(S): Kanai, Kenichi; Goto, Kiyoto; Hashimoto, Kinji

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Factory, Inc., Japan

SOURCE: Eur. Pat. Appl., 71 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 254259	A2	19880127	EP 1987-110503	19870720 <--
EP 254259	A3	19891123		
R: AT, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AU 8775799	A	19880128	AU 1987-75799	19870717 <--
AU 590935	B2	19891123		
DK 8703774	A	19880122	DK 1987-3774	19870720 <--
US 4868183	A	19890919	US 1987-75910	19870720 <--
JP 01025756	A	19890127	JP 1987-183099	19870721 <--
JP 06051679	B	19940706		
JP 02138265	A	19900528	JP 1988-8846	19880118 <--
JP 06067911	B	19940831		
JP 02138251	A	19900528	JP 1989-210376	19890815 <--
JP 05071590	B	19931007		
US 5059598	A	19911022	US 1989-409192	19890919 <--
PRIORITY APPLN. INFO.:				
			JP 1986-172431	A 19860721
			JP 1986-213660	A 19860910
			JP 1987-38595	A 19870220
			JP 1987-94199	A 19870416
			US 1987-75910	A3 19870720
			JP 1987-183099	19870721

OTHER SOURCE(S): CASREACT 109:93070; MARPAT 109:93070

GI




AB The title compds. [I; R2 = alkyl; R2, R3 = H, alkyl; R2R3 = (CH2)4, CH:CH:CH:CH; R4 = 5- or 6-membered (substituted heteroaryl, including pyrazine-N-oxide, pyridazine-N-oxide, and pyrimidine-N-oxide but excluding thiazolyl, isothiazolyl, pyridyl, and 1,3,5-triazinyl] were prepared as lipooxygenase inhibitor and antiinflammatories. To 2,6-di-tert-butyl-1,4-benzoquinone and aminopyrazine in THF was added a suspension of TiCl4 in pyridine/dichloroethane and the mixture was refluxed to give 2,6-di-tert-butyl-1,4-pyrazinylaminophenol. The latter at 37 mg/kg orally gave a 50% reduction in carrageenan-induced paw edema in rats.

IT 114559-54-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antiinflammatory)

RN 114559-54-5 HCAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-(2-oxazolylamino)- (CA INDEX NAME)



=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	108.18	678.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-13.12	-13.12

STN INTERNATIONAL LOGOFF AT 11:56:17 ON 02 FEB 2009